Filters: Keyword is Buprenorphine [Clear All Filters]
"Opioid Dependence Treatment in the Emergency Department--Reply." JAMA 314, no. 8 (2015): 835.
"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females." The pharmacogenomics journal 14, no. 3 (2014): 303-8. Abstract
"HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment." Journal of addiction medicine 7, no. 6 (2013): 410-6. Abstract
"A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice." Expert review of clinical pharmacology 6, no. 3 (2013): 249-69. Abstract
"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes." Drug and alcohol dependence 131, no. 1-2 (2013): 127-35. Abstract
"Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine." American journal of preventive medicine 44, no. 1 Suppl 2 (2013): S86-90.
"Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study." Journal of addiction medicine 6, no. 3 (2012): 205-11. Abstract
"Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians." Journal of addiction medicine 6, no. 2 (2012): 159-65. Abstract
"Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone." Journal of addiction medicine 6, no. 4 (2012): 274-9. Abstract
"Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia." PloS one 7, no. 12 (2012): e50673. Abstract
"Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients." Drug and alcohol dependence 118, no. 2-3 (2011): 326-34. Abstract
"The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S7-13. Abstract
"The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S76-82. Abstract
"Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S62-7. Abstract
"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S54-61. Abstract
"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S68-75. Abstract
"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S33-8. Abstract
"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S14-21. Abstract
"Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone." The American journal of drug and alcohol abuse 37, no. 4 (2011): 224-8. Abstract
"Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al." Journal of acquired immune deficiency syndromes (1999) 58, no. 4 (2011): e112; author reply e112-3.
"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial." Archives of general psychiatry 68, no. 12 (2011): 1238-46. Abstract
"Oral substitution treatment of injecting opioid users for prevention of HIV infection." Cochrane database of systematic reviews (Online), no. 8 (2011): CD004145. Abstract
"The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment." Journal of general internal medicine 25, no. 9 (2010): 936-41. Abstract
"Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial." Addictive behaviors 35, no. 5 (2010): 537-40. Abstract
"Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial." Annals of internal medicine 152, no. 11 (2010): 704-11. Abstract
"Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone." Journal of general internal medicine 25, no. 7 (2010): 670-4. Abstract
"Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment." Journal of urban health : bulletin of the New York Academy of Medicine 87, no. 4 (2010): 592-602. Abstract
"The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 19, no. 1 (2010): 53-8. Abstract
"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 19, no. 1 (2010): 4-16. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir." Journal of acquired immune deficiency syndromes (1999) 54, no. 5 (2010): 511-4. Abstract
"Assessing social risks prior to commencement of a clinical trial: due diligence or ethical inflation?" The American journal of bioethics : AJOB 9, no. 11 (2009): 48-54. Abstract
"Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients." Drug and alcohol dependence 99, no. 1-3 (2009): 132-40. Abstract
"Integrating buprenorphine treatment into office-based practice: a qualitative study." Journal of general internal medicine 24, no. 2 (2009): 218-25. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
"Factors affecting willingness to provide buprenorphine treatment." Journal of substance abuse treatment 36, no. 3 (2009): 244-51. Abstract
"Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening." The American journal of drug and alcohol abuse 35, no. 6 (2009): 439-44. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
"Treatment of adolescent opioid dependence: no quick fix." JAMA : the journal of the American Medical Association 300, no. 17 (2008): 2057-9.
"Narrative review: buprenorphine for opioid-dependent patients in office practice." Annals of internal medicine 148, no. 9 (2008): 662-70. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners." Journal of opioid management 4, no. 2 (2008): 81-6. Abstract
"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial." Lancet 371, no. 9631 (2008): 2192-200. Abstract
"Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors." Journal of substance abuse treatment 35, no. 1 (2008): 87-92. Abstract
"Case series of buprenorphine injectors in Kuala Lumpur, Malaysia." The American journal of drug and alcohol abuse 34, no. 4 (2008): 511-7. Abstract
"Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?" CNS drugs 22, no. 2 (2008): 99-111. Abstract
